Skip to main content

Advertisement

SpringerLink
Log in

A pilot randomized trial of pentoxifylline for the reduction of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention

  • Clinical Trial
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

Periprocedural myocardial injury (PMI) following percutaneous coronary intervention (PCI) has received great attention due to its significant association with mortality and morbidity. Accordingly, cardioprotection during PCI is one of the important therapeutic concerns. Regarding the potential cardiovascular benefits of pentoxifylline this study was performed to evaluate whether the pretreatment pentoxifylline could reduce PMI in patients who are undergoing elective PCI.

Methods

A randomized clinical trial on 85 patients undergoing elective PCI was performed. The intervention group (n = 41) received 1200 mg pentoxifylline in divided doses plus the standard treatment before PCI, while the control group (n = 44) received the standard treatment. For assessing myocardial damage during PCI, the levels of CK-MB and troponin-I were measured at baseline, 8, and 24 h after the procedure. Then, patients were followed up for a 1-month period regarding the major adverse cardiac effect.

Results

Comparing with the control group, no significant change of CK-MB at 8 (p = 0.315) and 24 h (p = 0.896) after PCI was documented in pentoxifylline group. Similarly, no significant change was found in troponin-I at 8 (p = 0.141) and 24 h (p = 0.256) after PCI.

Conclusions

This study could not support the pretreatment with pentoxifylline in the prevention of PMI in patients undergoing elective PCI. However, the trend was toward the potential benefit of pentoxifylline.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Cook S, Walker A, Hugli O, Togni M, Meier B (2007) Percutaneous coronary interventions in Europe: prevalence, numerical estimates, and projections based on data up to 2004. Clin Res Cardiol 96:375–382

    Article  PubMed  Google Scholar 

  2. Moschovitis A, Cook S, Meier B (2010) Percutaneous coronary interventions in Europe in 2006. Euro Intervention 6:189–194

    PubMed  Google Scholar 

  3. American Heart Association (2009). Heart Disease and Stroke Statistics—2009 Update. &2009, American Heart Association

  4. Popma JJ, Kuntz RE, Baim DS (2002) A decade of improvement in the clinical outcomes of percutaneous coronary intervention for multivessel coronary artery disease. Circulation 106:1592–1594

    Article  PubMed  Google Scholar 

  5. Bhatt DL, Topol EJ (2005) Does creatine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes. Circulation 112:906–915

    Article  CAS  PubMed  Google Scholar 

  6. Thygesen K, Alpert JS, White HD (2007) Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol 50:2173–2195

    Article  PubMed  Google Scholar 

  7. Babu GG, Walker JM, Yellon DM, Hausenloy DJ (2011) Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J 32(1):23–31

    Article  CAS  PubMed  Google Scholar 

  8. Ioannidis JP, Karvouni E, Katritsis DG (2003) Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. J Am Coll Cardiol 42:1406–1411

    Article  CAS  PubMed  Google Scholar 

  9. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al (2006) ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113(7):e166–e286

    Article  PubMed  Google Scholar 

  10. Zhang M, Xu Y-J, Mengi SA, Arneja AS, Dhalla NS (2004) Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases. Exp Clin Cardiol 9(2):103–111

    CAS  PubMed Central  PubMed  Google Scholar 

  11. Testa L, Van Gaal WJ, Biondi Zoccai GG, Agostoni P, Latini RA, Bedogni F, Porto I, Banning AP (2009) Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM 102:369–378

    Article  CAS  PubMed  Google Scholar 

  12. Nienhuis MB, Ottervanger JP, Bilo HJ, Dikkeschei BD, Zijlstra F (2008) Prognostic value of troponin after elective percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 71:318–324

    Article  PubMed  Google Scholar 

  13. Akkerhuis KM, Alexander JH, Tardiff BE, Boersma E, Harrington RA, Lincoff AM, Simoons ML (2002) Minor myocardial damage and prognosis: are spontaneous and percutaneous coronary intervention-related events different? Circulation 105:554–556

    Article  PubMed  Google Scholar 

  14. Simoons ML, van den Brand M, Lincoff M, Harrington R, van der Wieken R, Vahanian A, Rutsch W, Kootstra J, Boersma E, Califf RM, Topol E (1999) Minimal myocardial damage during coronary intervention is associated with impaired outcome. Eur Heart J 20:1112–1119

    Article  CAS  PubMed  Google Scholar 

  15. Pasceri V, Patti G, Nusca A, Pristipino C, Richichi G, Di Sciascio G (2004) Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of Myocardial Damage during Angioplasty) study. Circulation 110:674–678

    Article  CAS  PubMed  Google Scholar 

  16. Briguori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A (2009) Novel approaches for preventing or limiting events (Naples) II: trial impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 54:2157–2163

    Article  CAS  PubMed  Google Scholar 

  17. Patti G, Pasceri V, Colonna G, Miglionico M, Fischetti D, Sardella G, Montinaro A, Di Sciascio G (2007) Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 49:1272–1278

    Article  CAS  PubMed  Google Scholar 

  18. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A (2009) Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 54:558–565

    Article  PubMed  Google Scholar 

  19. Yun KH, Jeong MH, Oh SK, Rhee SJ, Park EM, Lee EM, Yoo NJ, Kim NH, Ahn YK, Jeong JW (2009) The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome. Int J Cardiol 137:246–251

    Article  PubMed  Google Scholar 

  20. Merla R, Reddy NK, Wang FW, Uretsky BF, Barbagelata A, Birnbaum Y (2007) Meta-analysis of published reports on the effect of statin treatment before percutaneous coronary intervention on periprocedural myonecrosis. Am J Cardiol 100:770–776

    Article  CAS  PubMed  Google Scholar 

  21. Wang FW, Osman A, Otero J, Stouffer GA, Waxman S, Afzal A, Anzuini A, Uretsky BF (2003) Distal myocardial protection during percutaneous coronary intervention with an intracoronary beta-blocker. Circulation 107:2914–2919

    Article  PubMed  Google Scholar 

  22. Lee CH, Low A, Tai BC, Co M, Chan MY, Lim J, Lim YT, Tan HC (2007) Pretreatment with intracoronary adenosine reduces the incidence of myonecrosis after nonurgent percutaneous coronary intervention: a prospective randomized study. Eur Heart J 28:19–25

    Article  PubMed  Google Scholar 

  23. Foroughinia F, Salamzadeh J, Namazi MH (2013) Protection from procedural myocardial injury by omega-3 polyunsaturated fatty acids (PUFAs): is related with lower levels of creatine kinase-MB (CK-MB) and troponin-I? Cardiovasc Ther 31(5):268–273

    Article  CAS  PubMed  Google Scholar 

  24. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M (2008) Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359:473–481

    Article  CAS  PubMed  Google Scholar 

  25. Ward A, Clissold SP (1987) Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 34:50–97

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We would like to thank the Cardiovascular Research Center and Shahid Madani Heart Center of Tabriz University of Medical Sciences for support of the study.

Conflict of interest

The authors declare that they have not any conflict of interest about this work.

Founding

None

Author information

Authors and Affiliations

  1. Cardiovascular Research Center, Shahid Madani Heart Center, Tabriz University of Medical Sciences, Tabriz, Iran

    Naser Aslanabadi, Hamid Reza Shirzadi, Samad Ghaffari, Bahram Sohrabi & Taher Entezari-Maleki

  2. Drug Applied Research Center and Department of Clinical Pharmacy, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

    Hadi Hamishehkar & Taher Entezari-Maleki

  3. Student Research Committee, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran

    Hossein Asghari-Soufi

  4. Department of Pediatrics, Children’s Hospital, Tabriz University of Medical Sciences, Tabriz, Iran

    Samaneh Dousti

  5. The Liver and Gastrointestinal Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

    Simin Ozar Mashayekhi

Authors
  1. Naser Aslanabadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hamid Reza Shirzadi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hossein Asghari-Soufi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Samaneh Dousti
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Samad Ghaffari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Bahram Sohrabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Simin Ozar Mashayekhi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hadi Hamishehkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Taher Entezari-Maleki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Taher Entezari-Maleki.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOCX 35 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aslanabadi, N., Shirzadi, H.R., Asghari-Soufi, H. et al. A pilot randomized trial of pentoxifylline for the reduction of periprocedural myocardial injury in patients undergoing elective percutaneous coronary intervention. Eur J Clin Pharmacol 71, 143–149 (2015). https://doi.org/10.1007/s00228-014-1782-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-014-1782-y

Keywords

Search

Navigation